ReviewFrontiers in bioengineering and biotechnology2020
Hydrogel Biomaterials for Application in Ocular Drug Delivery.
Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed.
- Emerging RNA-Based Therapeutic Strategies for Inflammatory Ophthalmic Disorders of the Anterior Segment: Mechanistic Insights and Translational Potential.ACS pharmacology & translational science · 2026Review
- Advanced Ophthalmic Drug Delivery in Homocystinuria Type CblC: A Translational Review of Ophthalmic Pathologies and Therapeutic Opportunities.Pharmaceutics · 2026Review
- Preservation and Reuse of KLEx Lenticules: From Biobanking to Therapeutic and Refractive Innovations.Bioengineering (Basel, Switzerland) · 2026Review
- A Systems View of Posterior Capsule Opacification: TGF-β/ROS Signaling, Mitochondrial Homeostasis, and Injury/Aging Cues-Therapeutic Opportunities.Investigative ophthalmology & visual science · 2026Review
- Light-Triggered and Sustained Delivery of Dexamethasone Using Chitosan-Coated PLGA Nanoparticles for Posterior Eye Disease Treatment.ACS omega · 2026Article
- Punctal and Intracanalicular Drug Delivery Systems for Ophthalmic Use: A Narrative Review of Technologies, Clinical Outcomes, and Critical Quality Attributes.Pharmaceutics · 2026Review
- Harnessing nanotechnology: Transforming ocular drug delivery with advanced hydrogel systems.Bioengineering & translational medicine · 2026Review
- Photopolymerizable Imidazolium Methacrylate Networks for Controlled Dexamethasone Release: Potential Application in Uveitis Therapy.ACS omega · 2026Article
- Prosthetic Corneal Surgery: A Narrative Review of Current Keratoprostheses and the Future Prospects of New Biomaterials.Bioengineering (Basel, Switzerland) · 2026Review
- Hydrogels-Advanced Polymer Platforms for Drug Delivery.Polymers · 2026Review
- Corneal Extracellular Vesicles: Small Packages with a Big Impact.Pharmaceutics · 2026Review
- Hydrogels as Promising Carriers for Ophthalmic Disease Treatment: A Comprehensive Review.Gels (Basel, Switzerland) · 2026Review
- Bridging Preclinical and Clinical Gaps in Ocular Therapeutics: Hydrogel Drug Delivery and 3D Tissue Models.International journal of nanomedicine · 2026Review
- Advances in dry eye disease: from immunopathological mechanisms to emerging ophthalmic drug delivery systems.Frontiers in medicine · 2026Review
- External stimuli-responsive drug delivery to the posterior segment of the eye.Drug delivery · 2025Review
- Hydrogel Films in Biomedical Applications: Fabrication, Properties and Therapeutic Potential.Gels (Basel, Switzerland) · 2025Review
- Prophylactic adjuvant therapy for postoperative recurrence of urethral stricture: a narrative review.Translational andrology and urology · 2025Review
- Gellan gum/gelatin Schiff-base hydrogel for ocular drug delivery of timolol maleate.BMC biotechnology · 2025Article
- Article
- In Situ Forming Poloxamer-Based Thermo-Sensitive Hydrogels for Ocular Application: A Focus on the Derivatives 407 and 188.Gels (Basel, Switzerland) · 2025Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are many challenges involved in ocular drug delivery. These are a result of the many tissue barriers and defense mechanisms that are present with the eye; such as the cornea, conjunctiva, the blinking reflex, and nasolacrimal drainage system. This leads to many of the conventional ophthalmic preparations, such as eye drops, having low bioavailability profiles, rapid removal from the administration site, and thus ineffective delivery of drugs. Hydrogels have been investigated as a delivery system which is able to overcome some of these challenges. These have been formulated as standalone systems or with the incorporation of other technologies such as nanoparticles. Hydrogels are able to be formulated in such a way that they are able to change from a liquid to gel as a response to a stimulus; known as "smart" or stimuli-responsive biotechnology platforms. Various different stimuli-responsive hydrogel systems are discussed in this article. Hydrogel drug delivery systems are able to be formulated from both synthetic and natural polymers, known as biopolymers. This review focuses on the formulations which incorporate biopolymers. These polymers have a number of benefits such as the fact that they are biodegradable, biocompatible, and non-cytotoxic. The biocompatibility of the polymers is essential for ocular drug delivery systems because the eye is an extremely sensitive organ which is known as an immune privileged site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.